Biomarker of sensitivity to PR-104 in leukemia

Abstract

In this issue of Blood, the paper by Moradi Manesh et al1 reports that PR-104 represents a potential novel treatment of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL) and that aldo-keto reductase 1C3 (AKR1C3) expression could be used as a biomarker to select patients who may respond to PR-104 in prospective clinical trials.